| ۱ | Inter-BRCT linker is probably the most intolerant region of the BRCA1 BRCT domain | Yadegari, F., Farahmand, L., Esmaeili, R., Zarinfam, S., Majidzadeh-A, K. | Journal of Biomolecular Structure and Dynamics | 2024 |
| ۲ | Synthesis of the scFv fragment of anti-Frizzled-7 antibody and evaluation of its effects on triple-negative breast cancer in vitro study | Khodaverdi, E., Shabani, A.A., Madanchi, H., Farahmand, L. | Clinical and Translational Oncology | 2024 |
| ۳ | Anti-MUC1 nanobody can synergize the Tamoxifen and Herceptin effects on breast cancer cells by inducing ER, PR and HER2 overexpression | Shokrollahi Barough, M., Jalili, N., Shafiee, S., (...), Hosseinzadeh, A., Farahmand, L. | International Immunopharmacology | 2023 |
| ۴ | Production of novel recombinant anti-EpCAM antibody as targeted therapy for breast cancer | Mirzaei, R., Shafiee, S., Vafaei, R., (...), Reza Esmailinejad, M., Farahmand, L. | International Immunopharmacology | 2023 |
| ۵ | Synthesized Anti-HER2 Trastuzumab-MCC-DM1 Conjugate: An Evaluation of Efficacy and Cytotoxicity | Shafiee, S., Mirzaei, R., Salehi, M., (...), Taheri, A., Farahmand, L. | Iranian Journal of Immunology | 2023 |
| ۶ | Development of a MET-targeted single-chain antibody fragment as an anti-oncogene targeted therapy for breast cancer | Vafaei, R., Khaki, Z., Salehi, M., (...), Mirzaei, R., Farahmand, L. | Investigational New Drugs | 2023 |
| ۷ | Anti-MUC1 nanobody conjugated by chitosan nanoparticle with enhancement of anti-proliferation activity in breast cancer cell lines | Khodabakhsh, F., Shokri, S., Jalili, N., (...), Dashtestani, F., Farahmand, L. | Chemical Papers | 2023 |
| ۸ | Synthesis of Succinimidyl 4-(N-maleimidomethyl)-Cyclohexane-1-Carboxylate (SMCC) as a Linker and Conjugating Trastuzumab to Maytansinoid Derivative (DM1) Through SMCC as an Antibody-Drug Conjugate | Ahani, M., Salarian, M., Salehi, M., (...), Taheri, A., Farahmand, L. | Pharmaceutical Chemistry Journal, | 2023 |
| ۹ | Recombinant nanobody against MUC1 tandem repeats inhibits growth, invasion, metastasis, and vascularization of spontaneous mouse mammary tumors | Merikhian, P., Darvishi, B., Jalili, N., (...), Rahbarizadeh, F., Farahmand, L. | Molecular Oncology | 2022 |
| ۱۰ | Comparison of mucin-1 in human breast cancer and canine mammary gland tumor: a review study | Vafaei, R., Samadi, M., Hosseinzadeh, A., (...), Khaki, Z., Farahmand, L. | Cancer Cell International | 2022 |
| ۱۱ | Recognition of functional genetic polymorphism using ESE motif definition: a conservative evolutionary approach to CYP2D6/CYP2C19 gene variants | Samadi, M., Beigi, L., Yadegari, F., (...), Eskordi, M., Farahmand, L. | Genetica | 2022 |
| ۱۲ | Anti-cancer therapeutic strategies based on HGF/MET, EpCAM, and tumor-stromal cross talk | Barzaman, K., Vafaei, R., Samadi, M., (...), Dinvari, H., Farahmand, L. | Cancer Cell International | 2022 |
| ۱۳ | MUC1 is a potential target to overcome trastuzumab resistance in breast cancer therapy | Hosseinzadeh, A., Merikhian, P., Naseri, N., Eisavand, M.R., Farahmand, L. | Cancer Cell International | 2022 |
| ۱۴ | Quantitative Phosphoproteomics and Acetylomics of Safranal Anticancer Effects in Triple-Negative Breast Cancer Cells | Ashrafian, S., Zarrineh, M., Jensen, P., (...), Ghassempour, A., Larsen, M.R. | Journal of Proteome Research | 2022 |
| ۱۵ | Matrix stiffening and acquired resistance to chemotherapy: concepts and clinical significance | Darvishi, B., Eisavand, M.R., Majidzadeh-A, K., Farahmand, L. | British Journal of Cancer | 2022 |
| ۱۶ | Synthesis and characterization of smart stimuli-responsive herbal drug-encapsulated nanoniosome particles for efficient treatment of breast cancer | Akhlaghi, M., Taebpour, M., Lotfabadi, N.N., (...), Rahmanian, M., Tofighi, D. | Nanotechnology Reviews | 2022 |
| ۱۷ | Correction: Engineered hypoxia-responding Escherichia coli carrying cardiac peptide genes, suppresses tumor growth, angiogenesis and metastasis in vivo (Journal of Biological Engineering | Samadi, M., Majidzadeh-A, K., Salehi, M., (...), Moradi-Kalbolandi, S., Farahmand, L. | Journal of Biological Engineering | 2022 |
| ۱۸ | A comprehensive reference for BRCA1/2 genes pathogenic variants in Iran: published, unpublished and novel | Majidzadeh-A, K., Zarinfam, S., Abdoli, N., (...), Salehi, M., Zamani, M. | Familial Cancer | 2022 |
| ۱۹ | Necroptosis triggered by ROS accumulation and Ca2+ overload, partly explains the inflammatory responses and anti-cancer effects associated with 1Hz, 100 mT ELF-MF in vivo | Barati, M., Javidi, M.A., Darvishi, B., (...), Farahmand, L., Madjid Ansari, A. | Free Radical Biology and Medicine | 2021 |
| ۲۰ | Potential role of interferons in treating COVID-19 patients | Haji Abdolvahab, M., Moradi-kalbolandi, S., Zarei, M., (...), Majidzadeh-A, K., Farahmand, L. | International Immunopharmacology | 2021 |